Cargando…

MMSET is the key molecular target in t(4;14) myeloma

Detalles Bibliográficos
Autores principales:	Mirabella, F, Wu, P, Wardell, C P, Kaiser, M F, Walker, B A, Johnson, D C, Morgan, G J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2013
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3674460/ https://www.ncbi.nlm.nih.gov/pubmed/23645128 http://dx.doi.org/10.1038/bcj.2013.9

Ejemplares similares

Plasma Membrane Proteomics Identifies Biomarkers Associated with MMSET Overexpression in T(4;14) Multiple Myeloma
por: Xie, Zhigang, et al.
Publicado: (2013)

MB4-2/MB4-3 transcripts of IGH-MMSET fusion gene in t(4;14)(pos) multiple myeloma indicate poor prognosis
por: Li, Feng, et al.
Publicado: (2017)

MMSET: Role and Therapeutic Opportunities in Multiple Myeloma
por: Xie, Zhigang, et al.
Publicado: (2014)

A Novel Functional Role for MMSET in RNA Processing Based on the Link Between the REIIBP Isoform and Its Interaction with the SMN Complex
por: Mirabella, Fabio, et al.
Publicado: (2014)

The snoRNA target of t(4;14) in multiple myeloma regulates ribosome biogenesis
por: Oliveira, Vanessa, et al.
Publicado: (2019)

The mevalonate pathway is an actionable vulnerability of t(4;14)-positive multiple myeloma
por: Longo, Joseph, et al.
Publicado: (2020)

Targeting UCHL1 Induces Cell Cycle Arrest in High-Risk Multiple Myeloma with t(4;14)
por: Kamseng, Parin, et al.
Publicado: (2021)

Hypoxia-induced CREB cooperates MMSET to modify chromatin and promote DKK1 expression in multiple myeloma
por: Xu, Yinyin, et al.
Publicado: (2021)

Understanding the interplay between the proteasome pathway and autophagy in response to dual PI3K/mTOR inhibition in myeloma cells is essential for their effective clinical application
por: Aronson, L I, et al.
Publicado: (2013)

The t(4;14) translocation and FGFR3 overexpression in multiple myeloma: prognostic implications and current clinical strategies
por: Kalff, A, et al.
Publicado: (2012)

Super Enhancer-Mediated Upregulation of HJURP Promotes Growth and Survival of t(4;14)-Positive Multiple Myeloma
por: Jia, Yunlu, et al.
Publicado: (2022)

Inactivation of BANK1 in a novel IGH-associated translocation t(4;14)(q24;q32) suggests a tumor suppressor role in B-cell lymphoma
por: Yan, J, et al.
Publicado: (2014)

The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma
por: Touzeau, C, et al.
Publicado: (2014)

Posttranslational modification of Aurora A‐NSD2 loop contributes to drug resistance in t(4;14) multiple myeloma
por: Jiang, Hongmei, et al.
Publicado: (2022)

Implementation of KK for DELPHI (DElKK version 4.14/6)
por: Andringa, S, et al.
Publicado: (2003)

Re: JSLS. 2013;17:414–417. Effects of Electrosurgery and Vaginal Closure Technique on Postoperative Vaginal Cuff Dehiscence
por: Uccella, Stefano, et al.
Publicado: (2015)

Epigenomic reprogramming via HRP2-MINA dictates response to proteasome inhibitors in multiple myeloma with t(4;14) translocation
por: Wang, Jingjing, et al.
Publicado: (2022)

Concomitant 1q+ and t(4;14) influences disease characteristics, immune system, and prognosis in double-hit multiple myeloma
por: Ozga, Michael, et al.
Publicado: (2023)

P807: CLASS Ⅱ FERROPTOSIS INDUCERS ARE A NOVEL THERAPEUTIC APPROACH FOR T(4;14)-POSITIVE MULTIPLE MYELOMA
por: Zhang, Jiasi, et al.
Publicado: (2023)

MMSET dysregulates gene expression in myeloma through global and focal changes in H3K36 and H3K27 methylation
por: Popovic, Relja, et al.
Publicado: (2013)

Whole-body diffusion-weighted MRI: a new gold standard for assessing disease burden in patients with multiple myeloma?
por: Pawlyn, C, et al.
Publicado: (2016)

Reply to letters on review ‘Evolving treatment strategies for myeloma’
por: Morgan, G J, et al.
Publicado: (2005)

Inhibiting MEK in MAPK pathway-activated myeloma
por: Heuck, C J, et al.
Publicado: (2016)

Assessing the effect of obesity-related traits on multiple myeloma using a Mendelian randomisation approach
por: Went, M, et al.
Publicado: (2017)

MMSET/WHSC1 enhances DNA damage repair leading to an increase in resistance to chemotherapeutic agents
por: Shah, Mrinal Y., et al.
Publicado: (2016)

Recombinant immunotoxins targeting B-cell maturation antigen are cytotoxic to myeloma cell lines and myeloma cells from patients
por: Bera, T K, et al.
Publicado: (2018)

Scientific opinion on flavouring group evaluation 414 (FGE.414): 2‐hydroxy‐4‐methoxybenzaldehyde
por: Younes, Maged, et al.
Publicado: (2021)

Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms
por: Walker, Brian A, et al.
Publicado: (2013)

Planned withdrawal of dexamethasone after pomalidomide low-dose dexamethasone induction for lenalidomide-refractory multiple myeloma (ALLG MM14)
por: Kalff, Anna, et al.
Publicado: (2021)

Disentangling the microRNA regulatory milieu in multiple myeloma: integrative genomics analysis outlines mixed miRNA-TF circuits and pathway-derived networks modulated in t(4;14) patients
por: Calura, Enrica, et al.
Publicado: (2015)

Translocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patients
por: Walker, B A, et al.
Publicado: (2014)

Lack of BRAF V600E mutation in human myeloma cell lines established from myeloma patients with extramedullary disease
por: Lodé, L, et al.
Publicado: (2013)

The NSD2/WHSC1/MMSET methyltransferase prevents cellular senescence‐associated epigenomic remodeling
por: Tanaka, Hiroshi, et al.
Publicado: (2020)

COVID-19: impact of vaccination in myeloma patients
por: Hoornaert, E., et al.
Publicado: (2022)

A Novel Function of Sphingosine Kinase 2 in the Metabolism of Sphinga-4,14-Diene Lipids
por: Couttas, Timothy Andrew, et al.
Publicado: (2020)

MEK inhibitor, TAK-733 reduces proliferation, affects cell cycle and apoptosis, and synergizes with other targeted therapies in multiple myeloma
por: de la Puente, P, et al.
Publicado: (2016)

WDR26 and MTF2 are therapeutic targets in multiple myeloma
por: Sun, Fumou, et al.
Publicado: (2021)

Safe and effective use of outpatient non-myeloablative allogeneic stem cell transplantation for myeloma
por: Campbell, P, et al.
Publicado: (2014)

t(14;16)-positive multiple myeloma shows negativity for CD56 expression and unfavorable outcome even in the era of novel drugs
por: Narita, T, et al.
Publicado: (2015)

Molecular analysis of RAS-RAF tyrosine-kinase signaling pathway alterations in patients with plasma cell myeloma
por: Grossmann, V, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_mcoj09hs9kttjqeaas59jo9u5o